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Abstract
Background: Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin’s lymphoma. Bortezomib
is the first product to be approved for the treatment of patients with previously untreated MCL, for whom
haematopoietic stem cell transplantation is unsuitable, and is used in combination with rituximab, cyclophosphamide,
doxorubicin, vincristine and prednisone (VR-CAP). The National Institute of Health and Care Excellence recently
recommended the use of VR-CAP in the UK following a technology appraisal. We present the cost effectiveness
analysis performed as part of that assessment: VR-CAP versus the current standard of care regimen of rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in a UK setting.
Methods: A lifetime economic model was developed with health states based upon line of treatment and progression
status. Baseline patient characteristics, dosing, safety and efficacy were based on the LYM-3002 trial. As overall survival
data were immature, survival was modelled by progression status, and post-progression survival was assumed equal
across arms. Utilities were derived from LYM-3002 and literature, and standard UK cost sources were used.
Results: Treatment with VR-CAP compared to R-CHOP gave an incremental quality-adjusted life year (QALY) gain of
0.81 at an additional cost of £16,212, resulting in a base case incremental cost-effectiveness ratio of £20,043.
Deterministic and probabilistic sensitivity analyses showed that treatment with VR-CAP was cost effective at
conventional willingness-to-pay thresholds (£20,000–£30,000 per QALY).
Conclusions: VR-CAP is a cost-effective option for previously untreated patients with MCL in the UK.
Keywords: Bortezomib, Mantle cell lymphoma, Cost effectiveness, VR-CAP, R-CHOP
Background
Mantle cell lymphoma (MCL) is a rare, incurable and
aggressive sub-type of non-Hodgkin’s lymphoma (NHL),
accounting for approximately 6 % of all NHL cases [1].
The incidence of MCL in the UK is 0.9 per 100,000 [1].
The general pattern of disease progression in MCL is
one of relapse and remission, with each relapse becom-
ing more difficult to treat, and the depth and durability
of any subsequent remissions achieved invariably inferior
to those achieved with first-line treatment [2–6].
In patients first presenting with aggressive disease re-
quiring treatment, the initial treatment decision is whether
patients are suitable for high-intensity induction therapy,
to be followed by haematopoietic stem cell transplantation
(HSCT). There are no strict criteria against which patients
are assessed; rather, haematologists will assess eligibility
on a patient-by-patient basis, taking into account fac-
tors such as patient age, performance status and disease
prognosis, disease severity, co-morbidities, and clinical
risk [2, 5–10].
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For patients who are not eligible for high-intensity in-
duction therapy, that is those for whom HSCT is unsuit-
able, there had been no licensed induction therapy
regimens prior to bortezomib. Rituximab, cyclophospha-
mide, doxorubicin, vincristine and prednisone (R-CHOP)
became the preferred first-line induction therapy in UK
clinics because the large scale European MCL Elderly trial
[11] demonstrated a survival benefit for R-CHOP when
compared with rituximab in combination with fludarabine
and cyclophosphamide (R-FC). Alternative rituximab-
based chemotherapy induction regimens are also adminis-
tered in the first-line setting, but usually only for the
frailest of patients considered unsuitable for R-CHOP
therapy; while alternatives are considered to be associated
with lower toxicity, the evidence base supporting their use
is considerably weaker [12]. Median progression-free sur-
vival (PFS) associated with chemotherapy is less than
2 years, and median overall survival (OS) is less than
5 years [10, 13–19].
Bortezomib is the first product to be licensed for the
treatment of patients with previously untreated MCL for
whom HSCT is unsuitable. Bortezomib is administered
in combination with the rituximab, cyclophosphamide,
doxorubicin, prednisone backbone familiar to clinicians
as part of the R-CHOP regimen. A randomised, open-
label, multicentre Phase III study (LYM-3002) comparing
bortezomib, rituximab, cyclophosphamide, doxorubicin
and prednisolone (VR-CAP) to R-CHOP showed a signifi-
cant improvement in PFS (24.7 versus 14.4 months; hazard
ratio [HR] = 0.63, p < 0.001) based on the primary assess-
ment of PFS by the independent review committee (IRC)
[20]. Duration of overall response for VR-CAP was more
than double that of R-CHOP (median of 36.5 versus
15.1 months), resulting in an increase in the treatment free
interval (TFI) of almost 20 months versus R-CHOP (me-
dian of 40.6 versus 20.5 months; HR = 0.50, p < 0.001) [20].
There have been no previous technology appraisals by
the National Institute of Health and Care Excellence
(NICE) within MCL; other therapies that are frequently
used such as bendamustine and temsirolimus did not go
through the UK health technology assessment (HTA)
process due to lack of marketing authorisation approval
and manufacturer non-submission, respectively. To gain
NICE recommendation for VR-CAP, the cost effective-
ness of VR-CAP had to be assessed over the long term
and beyond the duration of clinical trial follow up. As
median survival for VR-CAP had not been reached in
the LYM-3002 trial, it was challenging to provide realis-
tic and robust estimates of long-term OS. This challenge
is common in UK HTAs and will become more pro-
nounced as regulatory and HTA bodies come under
pressure to provide earlier access to promising drugs.
The objective of this study was to assess the cost ef-
fectiveness of VR-CAP compared to R-CHOP, in a UK
setting, which is currently seen as standard first-line
treatment for patients with MCL.
Methods
Model structure
The cost-effectiveness model was developed as a Markov
model with five health states, representing pre- and
post-progression from first- and second-line treatment,
as well as death, as presented in Fig. 1. A hypothetical
cohort of patients enter the model when they start their
first-line treatment for MCL, and their progression
through the disease, including second-line treatment,
was followed until death. The model used a cycle length
of 1 week, at which time patients could move between
health states. The cycle length of 1 week was selected to
give sufficient granularity to capture short-term changes
in progression status. And a lifetime horizon of 20 years
was used in line with UK guidance; ≥94 % of patients
were modelled to have died within this time horizon
[21]. The model used the perspective of the UK National
Health Service, and a discount rate of 3.5 % per year for
costs and health outcomes as per UK guidance [21].
Population
The population included in the model was the intention
to treat population from the LYM-3002 trial; the only
Fig. 1 Model diagram. PFS, progression-free survival; PPS, post-progression survival; PrePS, pre-progression survival; TFI, treatment-free interval.
1. Modelled using survival function to PFS Kaplan–Meier data; 2. Modelled using survival function to TFI Kaplan–Meier data; 3. Modelled using
average duration of second-line treatment; 4. Modelled using survival function to PrePS Kaplan–Meier curve plus general population background
mortality data; 5. Modelled using survival function to PPS Kaplan–Meier curve
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trial investigating the comparative effectiveness of VR-
CAP and R-CHOP in MCL (this was confirmed in a
systematic literature review). A scenario analysis was
performed that included only patients clinically ineligible
for HSCT, as LYM-3002 also included patients that were
ineligible due to non-clinical reasons (e.g. HSCT was
not available or was refused by the patient). Baseline pa-
tient characteristics for both populations are presented
in Table 1.
Transitions between health states
Transitions between health states in the model were
based on LYM-3002 data. In addition to PFS by IRC,
which was the primary outcome, PFS was also assessed
by the investigator and in an alternative IRC assessment.
In the primary IRC assessment, patients were classified
as progressed when the disease seemed to have wors-
ened based on the International Workshop Response
Criteria, on one computerised tomography scan. In the
alternative IRC assessment, this could be revised de-
pending on whether a lesion was assessed as resolved or
persisting at subsequent time points by the IRC. The al-
ternative IRC assessment of PFS was considered to more
closely reflect clinical practice, where more than one
scan would be used to assess progression [22]. Scenario
analyses were performed to test the impact of the dif-
ferent assessment methods on the model outcomes. To
extrapolate beyond the duration of the clinical trial,
six different survival functions (exponential, gamma,
Gompertz, log-logistic, log-normal and Weibull) were
fitted to these PFS trial data, following NICE Decision
Support Unit guidance [23]. The choice between
survival models was based upon statistical goodness
of fit measured using the Akaike information criterion
and the Bayesian information criterion (Table 2), vis-
ual fit to the trial Kaplan–Meier data, and the validity
of the projected survival estimates as assessed by
practicing haematologists. The log-logistic model was
seen as the most reflective of outcomes observed in
clinical practice, and this was therefore used in the
model base case (Fig. 2).
Because of the immaturity of OS data, survival func-
tions were stratified by progression status at the end of
the trial (pre-progression survival [PrePS] and post-
progression survival [PPS]). For non-progressed patients
this was also stratified by trial arm. PPS was assumed
equal across model arms. This was justified by the obser-
vation that PPS was similar for the VR-CAP and R-CHOP
arms in the LYM-3002 trial [24], and the expectation that
different prior treatments would not be expected to im-
pact PPS [12]. Finally, two studies identified in a literature
review of surrogate endpoints in MCL also indicated that
PFS may be an appropriate surrogate for OS [25, 26].
Because the long-term projections of PrePS based on
extrapolation were quite high, presumably due to the
relative immaturity of data, it was decided that non-
disease-specific mortality, based on age and gender,
should be added to these curves to better capture long-
term survival. This was included and based upon UK life
tables [27]. For PrePS and PPS, the exponential curves
were judged as most reflective of outcomes observed in
UK clinical practice (Fig. 3) [12].
Second-line treatment starts after a treatment-free
interval modelled using exponential survival functions
(Fig. 4). The distribution of patients over different treat-
ments as well as average duration of treatment (used as
a proxy for PFS from second-line treatment; 90 days for
both arms) were based on LYM-3002.
Adverse events
All adverse events (AEs) that happened at Grade 3 or
higher in at least 5 % of either treatment group, as well
as Grade 2 peripheral sensory neuropathy and Grade 3
or higher alopecia and sepsis, were included in the
model, with rates as reported within the LYM-3002 trial.
These were selected based on expectation of an import-
ant impact on costs, utility or both. The annual rate for
each AE was calculated from the number of events in
the LYM-3002 trial and the total patient years on treat-
ment. This annual rate was then used to calculate the
weekly probability of each AE.
In the model, red blood cell and platelet transfusions
were administered to patients to treat AEs and to avoid
having to decrease chemotherapy doses. Again, the
weekly probability of requiring a transfusion was based
on annual rates of administration in LYM-3002 [24].
Table 1 Baseline characteristics of all patients versus non-HSCT




for HSCT only (n = 407)
Age at baseline 64.29 65.82
Female 26.1 % 26.8 %
European Union 27.9 % 31.2 %
North America 2.9 % 6.3 %
Rest of the World 69.2 % 65.6 %
Stage II 6 % 6 %
Stage III 20 % 22 %
Stage IV 74 % 72 %
ECOG 0 40 % 43 %
ECOG 1 47 % 47 %
ECOG 2 13 % 10 %
Mean patient weight (kg) 70.59 70.03
Body surface area (m2) 1.80 1.79
Abbreviations: ECOG Eastern Cooperative Oncology Group, HSCT haematopoietic
stem cell transplantation
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Medical resource use and costs
All costs were based on 2013/2014 UK prices. Patient
level data from the LYM-3002 trial were used to model
the number of patients receiving first-line treatment per
treatment cycle. Dose reductions were also applied as
they were observed in the trial. Most of the drug doses
included in the analysis were based on patient weight or
body surface area. To calculate the number of vials re-
quired per administration, a distribution was fitted to
the patient characteristics observed in the trial. This was
then used to calculate the average cost per dose for all
patients [28]. Administration costs were applied for all
intravenous administrations; for oral drugs one adminis-
tration visit was assumed at the start of treatment. The
use of tests, scans and medical visits was based on advice
of UK haematologists and was assumed to vary by
treatment status and progression status (Table 3) [24].
Standard UK unit costs were used for treatment, ad-
ministration, concomitant medication, medical re-
source use, adverse events and terminal care [29–33].
Treatment, administration and end-of-life costs are
summarised in Table 4.
Table 2 Goodness of fit and model parameters for the PFS, PrePS and PPS curves
Exponential Weibull Log-logistic Log-Normal Gamma Gompertz
PFS VR-CAP Intercept 7.142 7.146 6.758 6.772 7.148 3.72
Scale N/A 1.011 0.839 1.567 1.007 N/A
Shape N/A N/A N/A N/A 1.007 −0.0001
AIC 603.623 605.604 608.385 616.888 607.603 1194.398
BIC 607.116 612.590 615.371 623.874 618.082 1201.384
PFS R-CHOP Intercept 6.571 6.566 6.138 6.134 6.374 3.087
Scale N/A 0.913 0.654 1.22 1.042 N/A
Shape N/A N/A N/A N/A 0.54 −0.005
AIC 634.079 634.075 622.425 636.948 630.674 1349.269
BIC 637.576 641.070 629.419 643.942 641.166 1356.263
PrePS and PPS Intercept 7.61 6.657 7.309 7.355 7.765 4.232
PrePS VR-CAP 1.511 1.635 1.685 1.979 1.573 1.511
Pre-PS R-CHOP 1.385 1.499 1.571 1.896 1.412 1.385
Scale N/A 1.083 0.964 1.883 1.749 N/A
Shape N/A N/A N/A N/A 1.749 0.002
AIC 915.60 916.37 920.84 929.16 917.11 1717.58
BIC 932.35 937.31 941.78 950.11 942.24 1738.52
Abbreviations: AIC Aikake information criterion, BIC Bayesian information criterion, PFS progression-free survival, PPS post-progression survival, PrePS pre-
progression survival, R-CHOP rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone, VR-CAP bortezomib with rituximab, cyclophosphamide,
doxorubicin and prednisolone
Fig. 2 Log-logistic PFS curves used in model base case. KM, Kaplan–Meier; PFS, progression-free survival; R-CHOP, rituximab with cyclophosphamide,
doxorubicin, vincristine and prednisolone; VR-CAP, bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisolone
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Quality of life
Utility scores ranging from 0 to 1, with 0 representing
death and 1 representing perfect health, defined the
quality of life of patients. In the LYM-3002 trial, utility
was measured using the EQ-5D at each cycle of treat-
ment and at the end-of-treatment visit, which was per-
formed 30 days after the last dose was administered.
These data were therefore used for the progression-free
and progressed from first-line treatment health states.
Patients that were progression-free from second-line
treatment were assumed to have the same utility as pa-
tients progression-free from first-line treatment (Table 5).
The economic literature was searched to identify utility
values for the progressed from second-line treatment
health state; values from aggressive NHL were selected
as there were no utilities published specifically for MCL
[34]. Decreases in utility for patients experiencing adverse
events were also modelled using weekly probabilities of
AEs and average durations of AEs from LYM-3002 trial
data.
Outcomes
The outcome used in this cost-effectiveness analysis was
the cost per quality-adjusted life year (QALY). QALYs
were calculated by multiplying the time a patient spent
in a specific health state by the utility value associated
with that health state. Average lifetime QALYs per pa-
tient were calculated as well as average lifetime costs.
These were used to calculate the incremental cost-
effectiveness ratio (ICER).
Sensitivity analysis
A series of one-way sensitivity analyses were performed
changing one parameter at a time to the upper and
Fig. 3 Exponential disease-specific OS curves used in model base case. KM, Kaplan–Meier; OS, overall survival; PrePS, pre-progression survival; PPS,
post-progression survival; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone; VR-CAP, bortezomib with
rituximab, cyclophosphamide, doxorubicin and prednisolone
Fig. 4 Exponential TFI curves used in model base case. KM, Kaplan–Meier; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and
prednisone; TFI, treatment-free interval; VR-CAP, bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone
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lower limit of their 95 % confidence interval, respect-
ively, holding all other parameters constant. This was
done to evaluate the sensitivity of the model to individ-
ual model inputs. Additionally, a probabilistic sensitivity
analysis (PSA) was performed where all parameters at
once were randomly sampled from their distribution.
This was iterated 1,000 times, so that the uncertainty
around the point estimate of the model outcome could
be tested. Through empirical testing it was found that
1,000 iterations were sufficient to capture the uncer-
tainty around the base case ICER.
Scenario analyses were also performed testing the as-
sumptions around PFS, OS and utilities, by changing as-
sumptions and using alternative data sources.
Validation
Because of the uncertainty in the extrapolation of OS
data due to immaturity of the data, a comparison of
model outcomes to long-term observational studies from
inside and outside the UK was made; this showed that
outcomes of the model were comparable with contem-
poraneous long-term datasets (Fig. 5). In comparison to
available observational datasets, the survival in the LYM-
3002 trial closely followed that reported by Abrahamsson
but was greater than that of Surveillance, Epidemiology,
and End Results Program (SEER) [35, 36]. Abrahamsson
et al. was a recent publication (2014) that reported the OS
of a European population (Swedish) and used a similar
treatment to the LYM-3002 trial (rituximab-based chemo-
therapy). In contrast, data from SEER are much older than
data from the LYM-3002 trial (2004–2007 versus 2008–
2011); the study was conducted in the US and included all
MCL treatments (i.e. was likely to include treatments that
were less efficacious than R-CHOP).
Results
As presented in Table 6, VR-CAP is associated with
higher costs and greater efficacy compared to R-CHOP.
The base case results demonstrate that VR-CAP is a cost
effective treatment at the conventional UK willingness-
to-pay threshold of £20,000–£30,000 per QALY [21]
with an ICER of £20,043. The PSA indicated that there
was a probability of 88.9 % that the ICER lies below the
threshold of £30,000 per QALY. Figure 6 indicates that
most uncertainty in the model comes from uncertainty
in efficacy.
Table 6 shows that VR-CAP patients have a longer
PFS, whereas R-CHOP patients spend more time in the
‘progressed from second-line treatment’ health state
than VR-CAP patients. This is due to the difference in
PFS, while PPS is assumed to be equal between arms,
generating a smaller difference in OS than PFS. The
treatment cost accounts for the majority of the overall
costs (Table 6), and therefore uncertainty around re-
source use and cost sources other than drug costs will
have only a minor impact on model outcomes.
One-way sensitivity analysis showed that uncertainty
in the parameters used within the model for PFS projec-
tions had the biggest impact on model outcomes to-
gether with the utility value applied to the ‘progressed
from second-line treatment’ health state (Fig. 7).
As can be seen from Table 7, the ICER is relatively in-
sensitive to the scenario analyses performed. Using dif-
ferent survival functions for PFS had the largest impact
on model outcomes, and alternative sources for utility
Table 3 Medical resource use for disease management by health state (Source of costs: NHS reference costs 2013–2014 [29])
On treatment (first- or second-line) Stable disease (off treatment) At time of
progression
Progressed Unit cost
Full blood count 3 per treatment cycle 1 per 2–3 monthsa 1 0 £3.00
Biochemistry 3 per treatment cycle 1 per 2–3 monthsa 1 0 £1.18
Blood glucose 3 per treatment cycle 0 0 0 £1.18
Computerised tomography scan In treatment Cycles 1, 3 and 6 0 1 0 £80.00
Haematologist visit In treatment Cycles 1, 3 and 6 1 per 2–3 monthsa 1 1 per 2–3 monthsa £150.06
Abbreviations: NHS National Health Service
aThis has been applied to the model as once every 11 weeks
Table 4 Cost inputs used in the model
Costs VR-CAP R-CHOP Source
Drug costs per treatment cycle £4,426 £2,383 MIMS 2015 [31], eMIT 2014 [32]
Administration costs first treatment cycle £1,116 £381 NHS reference costs 2013–2014 [29]
Administration costs per subsequent treatment cycle £980 £245 NHS reference costs 2013–2014 [29]
Cost per 90 days of second-line treatment & administration £11,442 £11,665 MIMS 2015 [31], eMIT 2014 [32]
Cost of care at end of life £6,018 £6,018 Addicott, 2008 [45], Curtis, 2014 [30]
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data for patients progressed from second-line treatment
had the largest impact on the ICER. Using different trial
assessments of PFS had only a limited impact on
outcomes.
Discussion
The base case ICER of £20,043 indicates that VR-CAP is
a cost-effective treatment option for patients with previ-
ously untreated MCL, using the standard UK threshold
of £20,000–30,000 per QALY.
In the analysis, PFS is used as a surrogate for OS. This
approach assumes that there is no survival benefit after
a patients disease has progressed following treatment.
When OS data were used directly to model cost effect-
iveness, the ICER increased slightly to £21,357. In this
scenario it is assumed that there is a continued benefit
of VR-CAP over R-CHOP after disease progression. The
observation that OS, as modelled in the base case, shows
a good reflection of the LYM-3002 data supports the use
of PFS as a surrogate in the base case. A targeted litera-
ture review of NICE appraisals for cancer drugs from
2010 onwards identified two recent examples where PFS
was used as a surrogate for OS either directly or indir-
ectly (by assuming the same post-progression survival
[PPS]) [37, 38]. In both cases, this methodology came
under substantial scrutiny. Additionally, three submis-
sions were identified where the same PPS was applied
for all treatment arms [39–41].
There are some differences between the LYM-3002
trial population and MCL patients in the UK. As is often
the case in clinical trials, the mean age of participants in
LYM-3002 (64 years) was relatively low, compared with
most patients who present at a median age of 73.5 in
clinical practice in the UK [42]. Additionally, only 30 %
of patients enrolled in LYM-3002 came from the European
Union or North America, with no patients included from
the UK. However, efficacy results showed consistency be-
tween geographic regions both in the size of benefit with
VR-CAP and the absolute PFS for R-CHOP. It is therefore
unlikely that the geographic spread of countries included
in the trial and the lack of UK patients had any relevant
impact upon the results.
The status of the OS data is the main uncertainty in
assessing the cost effectiveness of treatment. Despite the
conclusion that modelled OS was reasonably comparable
to long-term datasets, OS data for VR-CAP are imma-
ture. Once the final analysis of OS for LYM-3002 is
available, the model could be re-assessed to confirm ro-
bustness of the current analysis.
The model does not take into account rituximab main-
tenance (R-maintenance) treatment for patients that re-
spond to induction therapy, which has been adopted in
clinical practice in recent years based on the findings of
the European MCL Elderly trial [11]. At the time of initi-
ation of LYM-3002, R-maintenance was not commonly
adopted and thus was not included in the trial design.
There is a believe that R-maintenance therapy results in
similar benefit after any CHOP-like induction regimen,
and therefore we would expect to be able to give R-
maintenance after VR-CAP induction with a similar
Table 5 Utilities applied to the model










0.45 Doorduijn, 2005 [34]
Fig. 5 Modelled OS compared to observational datasets. MCL, mantle cell lymphoma; OS, overall survival; SEER, Surveillance, Epidemiology, and
End Results Program; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone; VR-CAP, bortezomib with rituximab,
cyclophosphamide, doxorubicin and prednisone
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extension to median survival times as observed with
R-maintenance after R-CHOP induction [43]. As the
European MCL Elderly trial was not designed to as-
sess the clinical efficacy of induction therapy with
versus without maintenance therapy, it could not be
used to model R-maintenance.
When submitted to NICE, the evidence review group
agreed that immature data may bias the extrapolation of
survival data, and had some concerns about the methods
used to overcome this. It was argued that if data are too
immature to model OS for all patients, it would be
questionable whether sufficient data are available to
Table 6 Discounted base case model outcomes
VR-CAP R-CHOP Differencea
Deterministic results
QALYs 4.10 3.29 0.81
Progression-free survival from first-line treatment 2.70 1.54 1.16
Progressed from first-line treatment 0.14 0.10 0.03
Progression-free survival from second-line treatment 0.12 0.15 −0.03
Progressed from second-line treatment 1.15 1.50 −0.35
Costs £45,842 £29,630 £16,212
First line therapy medication costs £22,606 £8,041 £14,566
Administration of first line therapy £5,817 £1,564 £4,253
Adverse events, transfusions & concomitant medication £1,472 £1,105 £367
Disease management costs £4,191 £4,676 −£486
Second line treatment (medication and administration) £7,152 £9,423 −£2,271
Terminal care £4,605 £4,821 −£217
Deterministic ICER (£/QALY gained) £20,043
Probabilistic results
QALYs 4.09 3.28 0.81
Costs £45,482 £29,285 £16,196
Probabilistic ICER (£/QALY gained) £19,889
Abbreviations: ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, R-CHOP rituximab with cyclophosphamide, doxorubicin, vincristine and
prednisolone, VR-CAP bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisolone
aSome differences due to rounding. First line therapy costs: medication costs of first line treatment; Administration costs: costs of administration of first-line
therapies; Adverse events and concomitant medication costs: costs associated with adverse events (treatment of adverse events, concomitant medication and
transfusions); Medical resource use; all costs for disease management, such as follow up visits and tests; Second line treatment costs; costs for medication and
administration of the subsequent line of treatment; Terminal care costs: costs for end-of-life care
Total costs and QALYs, as well as the ICERs are presented in bold text
Fig. 6 Cost-effectiveness plane from 1,000 PSA iterations. PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; WTP, willingness
to pay
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separately estimate long-term survival for patients with
and without progression. However, the uncertainty was
reduced for patients who had progressed as a smaller
proportion of patients at risk were still alive at the time
of evaluation. Furthermore, the data for the two treat-
ment arms is pooled and thereby the total sample size is
increased. The uncertainty of survival for patients who
had not progressed may be increased by using this
method, but this was accounted for by including general
population mortality for patients that had not yet
progressed. In doing so, it was assumed that all deaths
in the PrePS curves (prior to adjustment for background
mortality) in the trial were deaths from MCL. This was a
reasonable assumption as the number of deaths reported
in the LYM-3002 trial that were not due to progression
or toxicity was very low. Of the 69 deaths in total in the
VR-CAP group, there were only eight deaths that were
not due to progression or AEs. In the R-CHOP group,
there were a total of 87 deaths, of which 14 were not
due to progression or AEs [22].
Fig. 7 Tornado diagram displaying the ICER sensitivity to the ten most influential model inputs. ICER, incremental cost-effectiveness ratio; IV,
intravenous; OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone;
VR-CAP, bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone
Table 7 Results of scenario analyses
Scenario Incremental costs Incremental QALYs ICER
Exponential survival function for PFS £17,366 0.62 £27,789
Weibull survival function for PFS £17,055 0.64 £25,499
Log-normal survival function for PFS £15,921 0.77 £18,691
Gamma survival function for PFS £17,193 0.61 £27,318
Gompertz survival function for PFS £17,578 0.59 £30,099
Weibull survival function for PrePS and PPS £16,288 0.72 £20,368
Log-logistic survival function for PrePS and PPS £16,240 0.57 £22,284
Log-normal survival function for PrePS and PPS £16,256 0.47 £23,700
Gamma survival function for PrePS and PPS £16,332 0.81 £19,489
Gompertz survival function for PrePS and PPS £16,127 0.75 £19,905
Equal PrePS across arms £16,015 0.68 £20,639
OS by trial arm instead of PrePS and PPS £15,536 0.73 £21,357
Primary IRC assessment of PFS £16,009 0.65 £21,369
Investigator assessment of PFS £16,586 0.91 £18,737
Patients clinically ineligible for HSCT only £16,257 0.79 £20,195
All utilities based on Doorduijn 2005 [34] £16,212 0.75 £28,419
Using utility decrement for progressing based on Doorduijn 2005 [34] £16,212 0.69 £23,409
Abbreviations: HSCT hematopoietic stem cell transplantation, ICER incremental cost-effectiveness ratio, IRC independent review committee, OS overall survival, PFS
progression-free survival, PPS post-progression survival, PrePS pre-progression survival, QALY quality-adjusted life year
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A submission for HTA was also made to the Scottish
Medicines Consortium (SMC), who also noted that there
are limitations arising from the maturity of the survival
data, but found it unlikely that the approach taken
would cause substantial bias in favour of VR-CAP. The
SMC noted that this was supported by the literature
providing evidence of an association between PFS and
OS in MCL. In addition, it was noted that the modest
impact on the ICER from uncertainty associated with
varying survival inputs meant that the ICER for VR-CAP
was robust [44].
In 2015 both NICE and the SMC accepted the overall
approach taken in the cost-effectiveness model as a basis
for their conclusion that VR-CAP represents a cost-
effective treatment option for previously untreated MCL
for whom HSCT is unsuitable, in the UK [22, 44]. VR-
CAP is now recommended for use within the National
Health Service.
Conclusion
The current model shows that VR-CAP is a cost effective
treatment option for patients with previously untreated
MCL, for whom haematopoietic stem cell transplantation
is unsuitable, in the UK. Both NICE and SMC have rec-
ommended the use of VR-CAP in these patients.
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